Table 1.

Baseline characteristics of the study sample

CharacteristicsComplete Remission at Rituximab InitiationPartial Remission at Rituximab InitiationCombined
Number172239
Number with anti-PR3/anti-MPO11/613/924/15
Median age (range)63 (25 to 87)59.5 (39 to 88)60 (25 to 88)
Women (percent)6 (35%)14 (64%)20 (51%)
Median BVAS/WG at AAV diagnosis (range)5 (1 to 8)4.5 (1 to 9)5 (1 to 9)
Median BVAS/WG at rituximab initiation (range)0 (NA)2 (1 to 4)1 (1 to 4)
Median duration before rituximab, months (range)51 (3 to 282)71.5 (3 to 506)67 (3 to 506)
Number of relapses at rituximab initiation
    08513
    1 to 271118
    >2268
12 months of follow-up available11819
24 months of follow-up available61420
  • NA, not applicable.